Yuta Adachi

Dec 14, 2023 | nature.com | Yuta Adachi |Nicola J Armstrong |Stephanie Claire Bridgeman |Tuan Zea Tan |Jean Paul Thiery |Hiromichi Ebi | +1 more

AbstractDespite the promising antitumor activity of SHP2 inhibitors in RAS-dependent tumours, overall responses have been limited by their narrow therapeutic window. Like with all MAPK pathway inhibitors, this is likely the result of compensatory pathway activation mechanisms. However, the underlying mechanisms of resistance to SHP2 inhibition remain unknown. The E3 ligase SMURF2 limits TGFβ activity by ubiquitinating and targeting the TGFβ receptor for proteosome degradation.

Jun 5, 2023 | nature.com | Yuta Adachi |Rui Yamaguchi

Extended Data Fig. 1 Scrib mis-localization following KRAS G12C inhibition. a. The NCI-H358 KRAS G12C mutant lung cancer cell line was treated with 500 nM adagrasib for 48 hours. Representative immunofluorescence images of E-cadherin are shown. Scale bar, 10 μm. b. NCI-H358 cells were treated with 1 μM sotorasib at the indicated time points. Representative immunofluorescence images of Scrib are merged with 4’,6-diamidino-2-phenylindole (DAPI). Scale bar, 5 μm. c.